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protein (Weidemann et al., 1989), and FAD-linked muta-²Department of Neurosciences
tions in APP increase the amount, length, or fibrillogenic³Department of Neurology
properties of Ab species (Wisniewski et al., 1991; CitronJohns Hopkins School of Medicine
et al., 1992; Cai et al., 1993; Haass et al., 1994; SuzukiBaltimore, Maryland 21205
et al., 1994). Recent studies indicate that FAD mutant§The Mammalian Genetics Laboratory
PS1 alters APP processing to enhance the generation ofABL-Basic Research Program
Ab1±42 peptides, which appear to be more fibrillogenicNCI-Frederick Cancer Center for Research
than Ab1±40 (Jarrett et al., 1993). Patient plasma, asand Development
well as conditioned medium of fibroblast cultures fromFrederick, Maryland 21702
patients with FAD-linked PS1 and PS2 variants (Scheuner
et al., 1996) and conditioned medium from transfected
mammalian cells expressing mutant PS1 and PS2 vari-Summary
ants (Borchelt et al., 1996b; Duff et al., 1996; Citron et al.,
1997; Tomita et al., 1997), have been shown to containMissense mutations in two related genes, termed pre-
higher levels of Ab1±42 than relevant controls. To exam-senilin 1 (PS1) and presenilin 2 (PS2), cause dementia
ine the impact of mutant PS1 on Ab1±42 levels in an inin a subset of early-onset familial Alzheimer's disease
vivo setting, we produced transgenic mice that coex-(FAD) pedigrees. In a variety of experimental in vitro
press FAD mutant human (Hu) PS1-A246E and a chime-and in vivo settings, FAD-linked presenilin variants
ric mouse/human (Mo/Hu) APP695 harboring a Hu Abinfluence the processing of the amyloid precursor pro-
domain and mutations (K595N, M596L; Mullan et al.,tein (APP), leading to elevated levels of the highly fibril-
1992) linked to Swedish FAD pedigrees (APP swe; Bor-logenic Ab1±42 peptides that are preferentially depos-
chelt et al., 1996b). In comparison to transgenic miceited in the brains of Alzheimer Disease (AD) patients.
expressing APP swe alone or doubly transgenic miceIn this report, we demonstrate that transgenic animals
coexpressing wild-type Hu PS1 and APP swe, mice co-that coexpress an FAD-linked human PS1 variant
expressing Hu PS1-A246E and APP swe contained(A246E) and a chimeric mouse/human APP harboring
higher concentrations of Ab1±42 in brain tissue (Borcheltmutations linked to Swedish FAD kindreds (APP swe)
et al., 1996b). Similarly, mutant PS1 selectively influ-develop numerous amyloid deposits much earlier than
ences the processing of endogenous mouse APP andage-matched mice expressing APP swe and wild-type
wild-type human APP to increase production of Ab1±42Hu PS1 or APP swe alone. These results provide evi-
in transgenic mouse brains (Duff et al., 1996; Citron etdence for the view that one pathogenic mechanism
al., 1997).by which FAD-linked mutant PS1 causes AD is to ac-
In the present report, we examine the extent and fre-celerate the rate of b-amyloid deposition in brain.
quency of Ab deposits in 12-month-old transgenic mice
that coexpress Hu PS1-A246E and APP swe, mice that
Introduction
coexpress wild-type Hu PS1 and APP swe, mice that
express APP swe alone, and mice that express mutant
Alzheimer's disease (AD), the most common type of
PS1 alone. We demonstrate that only mice coexpressing
progressive dementia in the elderly, is characterized
Hu PS1-A246E and APP swe develop Ab deposits by
by neurofibrillary tangles and parenchymal deposits of
12 months of age. Moreover, we demonstrate that coex-
b-amyloid (Ab; Terry and Katzman, 1983). A subset of pression of Hu PS1-A246E with APP swe reduces the
AD cases occur relatively early (onset in the fourth to interval of the formation of initial Ab deposits from 18
sixth decade) and are familial (FAD) autosomal dominant months for APP swe alone to 9 months for APP swe
disorders caused by mutations in the presenilin 1 (PS1) with Hu PS1-A246E. These data providestrong evidence
gene on chromosome14 (St. George-Hyslop et al., 1992; in support of the hypothesis that a principal pathway
Alzheimer's Disease Collaborative Group, 1995; Chap- by which mutations in PS1 predispose individuals to
man et al., 1995; Cruts et al., 1995; Perez-Tur et al., FAD is to accelerate Ab deposition.
1995; Sherrington et al., 1995; Wasco et al., 1995; Boteva
et al., 1996; Campion et al., 1996; Sherrington et al., Results
1996), the presenilin 2 (PS2) gene on chromosome 1
(Levy-Lahad et al., 1995; Rogaev et al., 1995), or the To test directly whether the expression of FAD mutant
amyloid precursor protein (APP) gene on chromosome PS1 promotes amyloid deposition, we examined the
21 (McKhann et al., 1984; Chartier-Harlin et al., 1991; brains of aged (12-month-old) transgenic mice that
Goate et al., 1991; Naruse et al., 1991). Approximately coexpress Hu PS1-A246E and APP swe. In previous
examinations of younger (2- to 3-month-old) mice ex-
pressing these transgenes, we demonstrated that the‖ To whom correspondence should be addressed.
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Figure 1. Mice Coexpressing Hu PS1-A246E
and APP swe Develop Ab Deposits
(A±F) Twelve-month-old transgenic mice that
coexpress Hu PS1-A246E and APP swe ([A]
and [D]), APP swe alone ([B] and [E]), and Hu
PS1-A246E alone ([C] and [F]) were examined
by immunocytochemical staining for Ab pep-
tides with the monoclonal antibody 10D5.
(A±C) Hippocampus and occipital cortex
(magnification, 83).
(D±F) Frontal cortex (magnification, 203; in-
set in [D], 83).
(G±I) Sections (magnification, 203) of hippo-
campus from 12-month-old mice coexpress-
ing Hu PS1-A246E and APP swe stained with
10D5 (G), 6E10 (H), and 4G8 (I). The 4G8 anti-
body appears to preferentially recognize the
more compact deposits.
ratio of Ab1±42/43 to Ab1±40 is elevated by z50% in found in AD brain and in aged nonhuman primates (Mar-
tin et al., 1994).doubly transgenic mice expressing APP swe and Hu
PS1-A246E as compared with transgenic mice express-
ing APP swe alone or doubly transgenic mice coex- Wild-Type Hu PS1 Does Not Accelerate
Ab Depositionpressing wild-type Hu PS1 and APP swe (Borchelt et
al., 1996b). To determine whether the acceleration in Ab deposition
was due solely to the coexpression of Hu PS1 with APPBrain tissues from animals that coexpress Hu PS1-
A246E (line N-5) and APP swe (line C3±3) were stained swe, we examined the brains of age-matched 12-month-
old animals coexpressing APP swe (line C3±3) and wild-with Ab monoclonal antibodies (mAb) 10D5 (Games et
al., 1995), 4G8, and 6E10 (Kim et al., 1990); the latter type Hu PS1 (line S8±4; Figure 3). We document that, in
contrast to mice coexpressing APP swe and Hu PS1-antibody is specific for Hu Ab (Kim et al., 1990; Borchelt
et al., 1996a). The hippocampus (Figures 1A and 1G±1I) A246E, 12-month-old mice coexpressing APP swe and
wild-type Hu PS1 were free of Ab deposits (Figures 3Band frontal cortex (Figure 1D) of these animals invariably
contained numerous amyloid deposits that were immu- and 3D). Notably, previous characterizations of wild-
type Hu PS1 mRNA expression in line S8±4 demon-noreactive with all three antibodies (Figure 1G, 10D5;
Figure 1H, 6E10; Figure 1I, 4G8). The brains from age- strated that the levels of transgene-derived mRNA are
approximately fivefold higher in the S8±4 line than thematched littermates expressing APP695 swe alone
(Figures 1B and 1E) or from littermates expressing Hu N-5 line, which expresses Hu PS1-A246E (Thinakaran
et al., 1996; Lee et al., 1997). Thus, even when expressedPS1-A246E alone (Figures 1C and 1F) were free of Ab
deposits. Ab deposits (Figure 2A) were also detected at considerably higher levels than FAD-linked mutant
PS1, wild-type Hu PS1 neither elevates Ab1±42 produc-by conventional silver impregnation methods (Nakano
and Hirano, 1987; Figure 2B). Many of the large argen- tion (Borchelt et al., 1996b) nor promotes Ab deposition.
tophilic amyloid deposits contained dystrophic neurite
profiles (Figure 2B, arrowheads) that also showed APP FAD-Linked Hu PS1-A246E Dramatically Accelerates
the Rate of Ab Depositionimmunoreactivity with the APP-specific antibody CT15
(Sisodia et al., 1993; Borchelt et al., 1994), a reagent To determine the degree to which coexpression of Hu
PS1-A246E with APP swe accelerated the rate of amy-that has previously been used to visualize dystrophic
neurites in aged nonhuman primates (Martin et al., loid deposition, we compared the extent and frequency
of Ab deposits in 9-, 10-, and 11-month-old animals1994). Many deposits (Figure 2D) were also associated
with reactive astrocytes as revealed by immunostaining coexpressing APP swe and Hu PS1-A246E to that of
animals (of varied ages) expressing APP swe alone (Fig-with antibodies to glial fibrillary acidic protein (GFAP;
Figure 2E). Notably, nuclei with the features normally ure 4; Table 1). The number of Ab deposits in 9-month-
old animals coexpressing APP swe and Hu PS1-A246Eassociated with microglia were present in some of the
larger deposits (see Figure 2C). Thus, these datademon- were comparable to 18-month-old animals expressing
APP swe alone (compare Figures 4A and 4D; Table 1).strate, by multiple criteria (presence of Ab immunoreac-
tivity, argentophilic deposits, neuritic profiles, reactive The frequency of Ab deposits in mice coexpressing APP
swe and Hu PS1-A246E increased dramatically betweenastrocytosis), that animals coexpressing APP swe and
Hu PS1-A246E develop Ab deposits that resemble those 10 and 12 months of age (Figures 4B and 4C; Table 1),
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Figure 2. Mice Coexpressing Hu PS1-A246E
and APP swe Develop Amyloid Deposits and
Dystrophic Neurites Associated with Reac-
tive Gliosis
Twelve-month-old mice doubly transgenic
for Hu PS1-A246E and APP swe were exam-
ined by silver impregnation methods (Nakano
and Hirano, 1987) and immunostaining for Ab
(10D5), APP C-terminal epitopes (CT15), and
GFAP.
(A) A compact Ab deposit in the hippocampus
immunostained with the 10D5 antibody.
(B) A large Ab deposit in the hippocampus
with neurites stained by silver impregnation
methods (Nakano and Hirano, 1987); the dys-
trophic neurites are marked by arrowheads.
(C) A large plaque in the hippocampus stained
with APP-specific CT-15 antisera (Sisodia et
al., 1993; Borchelt et al., 1994).
(D) Ab deposits in the occipital cortex stained
by silver impregnation methods.
(E) The section adjacent to that shown in (D),
stained with anti-GFAP antibodies.
far exceeding the number of deposits in much older the brain (Borchelt et al., 1996a). Moreover, examina-
tions of brain tissues from 9- and 12-month-old micemice expressing APP swe alone. Collectively, these data
convincingly demonstrate that the Hu PS1-A246E acts expressing Hu PS1-A246E alone (n 5 4) showed normal
synergistically with APP swe to accelerate amyloid de-
position.
In our analyses of younger 9- and 10-month-old ani-
mals coexpressing APP swe and Hu PS1-A246E, it ap-
peared that the initial deposits were most frequently
observed in the hippocampus near the ventricles, in the
subiculum, and in theoccipital and frontal cortices. Even
up to the age of 12 months, Ab deposits have not been
detected in any region of the brain other than the cortex
and hippocampus (data not shown), despite relatively
high levels of expression of the transgene throughout
Figure 3. Ab Deposits Do Not Occur in 12-Month-Old Mice Coex-
pressing APP swe and Wild-Type Hu PS1
Figure 4. The Coexpression of Hu PS1-A246E with APP swe GreatlyThe brains of three 12-month-old and two 11-month-old mice coex-
Accelerates the Rate of Ab Depositionpressing APP swe and wild-type Hu PS1 were immunostained with
mAb 6E10 for Ab deposits. The brains of 9-, 10-, and 11-month-old animals coexpressing APP
swe and Hu PS1-A246E were compared to that of 18-month-old(A and C) Hippocampus and frontal cortex, respectively, of a 12-
month-old animal coexpressing APP swe and Hu PS1-A246E. animals expressing APP swe alone (these 18-month-old APP swe
mice were the dams of the double APP swe 3 PS1 transgenic(B and D) Hippocampus and frontal cortex of a 12-month-old animal
coexpressing APP swe and wild-type Hu PS1. animals). All sections were immunostained with mAb 6E10.
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Table 1. The Expression of Hu PS1-A246E Greatly Accelerates the Deposition of Ab in Mice Harboring APP swe Transgenes
Genotype n Age AB Deposits
APP swe 3 Hu PS1-A246E 2 9 months 1
2 10 months 11
2 11 months 111
4 12 months 111
APP swe 3 wild-type Hu PS1 2 11 months 2
3 12 months 2
Hu PS1-A246E 2* 12 months 2
2* 9 months 2
APP swe 1* 10 months 2
3* 12 months 2
2² 12 months 2
1² 14 months 2
4³ 18 months 1
1² 20 months 1
Because assigning numerical values to Ab-deposit loads is somewhat subjective, we chose to use an arbitrary unit system to classify the
relative Ab deposit loads of various animals. Animals with low numbers of Ab deposits per sagittal section through the cortex and hippocampus,
as exemplified by the 9-month-old APP swe 3 Hu PS1-A246E (Figure 4A) were assigned a single (1). Animals with 5±20 Ab deposits per
section (not counting small satellite deposits that surround the large neuritic deposits) were assigned (11), and animals with .20 Ab deposits
per section (not counting satellites) were assigned (111). APP swe and Hu PS1-A246E singly transgenic animals labeled with * are littermates
from the breedings of APP swe mice with the PS1 mice. APP swe animals labeled with ² are from a separate breeding colony of C3-3 APP
swe mice in hybrid backgrounds of C3H/HeJ and C57BL/6J mice. APP swe animals labeled with ³ are the APP swe transgenic dams ([C3H/
HeJ 3 C57BL/6J F3] 3 C57BL/6J n1) of all double transgenic litters.
patterns of cytology. The numbers of cortical and hippo- immunocytochemical studies, we obtained another set
of rabbit polyclonal antibodies that are specific forcampal neurons were not obviously diminished, and
neuritic abnormalities and reactive astrogliosis were not Ab1±40 and Ab1±42 (3540 and 3542, respectively) from
Drs. Heline Barelli and Frederic Checler (Institute of Mo-observed (data not shown). Thus, the presence of the
FAD-linked mutant Hu PS1-A246E appears to have no lecular and Cellular Pharmacology, Valbonne, France;
Barelli et al., 1997). Using these latter reagents, the pat-obvious impact on the mouse nervous system, apart
from its influence on amyloid deposition in cortical and terns of immunoreactivity in human AD brain and the
double transgenic mice were indistinguishable from thehippocampal regions.
patterns observed with Ab40 and Ab42.
Ab Deposits in Mice Coexpressing Hu PS1-A246E
and APP swe Contain Both Ab1±40 Discussion
and 1±42 Epitopes
To characterize the Ab deposits in mice coexpressing This report demonstrates that the coexpression of APP
swe with Hu PS1-A246E, but not wild-type Hu PS1,Hu PS1-A246E and APP swe, tissue sections were
stained with antisera Ab40 and Ab42, which are specific greatly accelerates the rate of Ab deposition in the
brains of transgenic mice. These new data extend ourfor Ab peptides terminating at amino acids 40 or 42,
respectively (Quality Control Biochemicals, Hopkinton, earlier studies of younger littermates that coexpress
APP swe and Hu PS1-A246E, in which we demonstratedMA). As previously reported, Ab deposits in human brain
were preferentially immunoreactive with the Ab42 anti- that only mutant PS1 influences APP processing in a
manner that leads to increased concentrations ofserum (Figure 5A; Iwatsubo et al., 1994, 1995, 1996;
Gravina et al., 1995; Lemere et al., 1996), and this immu- Ab1±42 in brain (Borchelt et al., 1996b). However, it is
not entirely clear whether the accelerated rate of Abnoreactivity was blocked by synthetic Ab1±42 peptides
(Figure 5B). In AD brain, Ab40 appeared to recognize deposition that occurs in the APP swe 3 Hu PS1-A246E
mice is due solely to increases in the levels of Ab1±42.only a subset of the very densely packed Ab deposits
(Figures 5C and 5D). In contrast, the majority of amyloid Based on in vitro aggregation studies (Jarrett et al.,
1993), which show Ab1±42 to be more fibrillogenic, anddeposits in both the cortex and hippocampus of the Hu
PS1-A246E 3 APP swe transgenic mice showed Ab40 immunocytochemical studies of brains from sporadic
AD (Iwatsubo et al., 1994; Gravina et al., 1995), Swedishimmunoreactivity (compare Figures 5E and 5G). The im-
munoreactivity of both antibodies in the brains of these kindreds of familial AD (Mann et al., 1996), and Down's
Syndrome (Iwatsubo et al., 1995; Lemere et al., 1996),transgenic mice was completely blocked by the relevant
peptide antigen (Figures 5F and 5H). Interestingly, in the which show that Ab1±42 is deposited early and selec-
tively, we predicted that the Ab deposits occurring insections from mouse brain, the numbers of Ab40 and
Ab42 immunoreactive deposits were lower than pre- our double transgenic mice would be immunoreactive
with antibodies to Ab1±42 (Borchelt et al., 1996b). How-dicted from 6E10 immunostaining or silver staining.
Moreover, both the Ab42 and Ab40 antibodies seemed ever, we discovered that the majority of Ab deposits in
our double transgenic mice were not immunoreactiveto be most reactive with the dense core structures in
the center of the deposit. To confirm the Ab42 and Ab40 with either of two polyclonal antisera to the C-terminus
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not recognized by antibodies to Ab1±42. Second, it is
possible that the Ab42 antibody discriminately recog-
nizes a specific conformation of Ab1±42 fibrils. However,
all tissues are denatured in 70% formic acid prior to
immunostaining. Third, Ab1±42 fibrils may, in mice, form
structures that are highly resistant to denaturants, thus
precluding detection. Finally, exoproteolytic activities in
mouse brain may degrade the deposited Ab1±42 pep-
tides to reveal the Ab40 epitope (which is removed more
slowly). Consistent with the latter two scenarios, Ab40
and Ab42 antisera recognized only z70% and 20%,
respectively, of the available Ab deposits. Moreover,
both antibodies appeared to preferentially reveal only
the most densely packed core of the deposit. Thus, it
is not presently clear whether the relative frequency and
intensity of immunostaining with the Ab40 and Ab42
antibodies accurately reflects antigen abundance or an-
tigen availability.
Although it is not clear whether increased Ab1±42 is
the only driving force behind the accelerated Ab deposi-
tion that occurred in our double transgenic mice, our
new findings add to the growing body of evidence sup-
porting the view (Selkoe, 1997) that amyloid deposition
is an early and critical event in the pathogenesis of AD.
Previous studieshave established that mutations in APP
occur in kindreds of familial AD (McKhann et al., 1984;
Chartier-Harlin et al., 1991; Goate et al., 1991; Naruse et
al., 1991) and that these mutations all alter proteolytic
processing to favor the formation of Ab1±42 peptidesFigure 5. Ab1±40 and 1±42 Are Codeposited in the Brains of APP
(Citron et al., 1992; Cai et al., 1993; Haass et al., 1994;swe 3 Hu PS1-A246E Mice
Suzuki et al., 1994). More recently, it has become clearAntibodies specific to the C-terminus of Ab1±40 (Ab40) and 1±42
(Ab42) were used to examine the relative deposition of Ab1±40 and that FAD-linked PS1 variants influence APP processing
1±42 in the brains of 12-month-old mice coexpressing APP swe and to promote the production of Ab1±42/43 peptides (Bor-
Hu PS1-A246E. As a control, sections from the cortex of an end- chelt et al., 1996b; Duff et al., 1996; Citron et al., 1997).
stage AD case were immunostained in parallel. Antibody specificity
Finally, immunocytochemical studies of brains from pa-was demonstrated by preincubating the antibody overnight in Tris-
tients with AD (Iwatsubo et al., 1994; Gravina et al., 1995)buffered saline with 10 mg/ml of peptide antigen. Notably, in addition
and Down's Syndrome (Iwatsubo et al., 1995; Lemereto the plaque immunostaining detected by Ab42, many neuronal
profiles appeared to be specifically stained (immunoreactivity was et al., 1996) indicate that Ab1±42 deposition is an early
completely competed with relevant peptide antigen). The signifi- event indisease pathogenesis. Adding to this large body
cance of this immunostaining is not clear at present, as no other of evidence, we now demonstrate that mutant PS1 acts
Ab antibody produced a similar pattern of immunostaining.
synergistically with mutant APP to markedly accelerate
Ab deposition in the CNS of transgenic mice. Collectively,
of Ab1±42 (Ab42 and 3542) but instead were stained these findings support the view that Ab deposition is an
with antisera to Ab1±40 (Ab40 and 3540). All immunore- early and significant event in the pathogenesis of AD.
activity with both sets of antibodies could be completely
competed with the relevant peptide antigen. Impor-
Experimental Procedurestantly, our analyses of human AD brain, using the poly-
clonal antibodies to Ab1±42 peptides, revealed large
Transgenic Micenumbers of Ab deposits, whereas the Ab1±40 antibodies
Most of the transgenic animals used in the present study are older
recognized relatively few deposits; these results are fully littermates of animals used in previous examinations of Ab peptide
consistent with earlier immunocytochemical studies levels (Borchelt et al., 1996b). All four genotypes examined (APP
swe 3 Hu PS1-A246E; APP swe 3 wild-type Hu PS1, APP swe only,with a variety of monoclonal antibodies (Iwatsubo et al.,
and Hu PS1-A246E only) were represented in offspring that were1994, 1995; Gravina et al., 1995; Lemere et al., 1996).
generated from matings between APP swe transgenic mice (strainThus, we believe that the antibodies used in our study
background 5 [C3H/HeJ 3 C57BL/6J F3] 3 C57BL/6J n1) and Hu
are selectively reactive with the C-termini of Ab1±40 and PS1-A246E transgenic mice (strain background 5 C3H/HeJ 3
Ab1±42. C57BL/6J F3). A subset of the older APP swe transgenic mice were
We envision several scenarios to explain our Ab1±40 from separate matings maintained in C3H/HeJ 3 C57BL/6J hybrid
backgrounds. All animals were maintained in pathogen-free micro-and 1±42 immunoreactivity data in the mice. First, Ab1±40
isolator cages.may be deposited more readily in mice; deposition of
Ab1±40 was observed in mice expressing high levels of
Hu APP695 with the Swedish mutations (Hsiao et al., Immunoctyochemistry and Histology
1996). However, this scenario does not explain why the Twelve-month-old transgenic mice that coexpress wild-type or Hu
PS1-A246E and APP swe, express APP swe alone, and express Humajority of deposits in our double transgenic mice were
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PS1-A246E alone were perfused with 13 Dulbecco's phosphate- Borchelt, D.R., Thinakaran, G., Eckman, C.B., Lee, M.K., Davenport,
F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., etbuffered saline (pH 7.1; Gibco BRL, Life Technologies, Grand Island,
al. (1996b). Familial Alzheimer's disease-linked presenilin 1 variantsNY) followed by 4% paraformaldehyde, bufferedwith 13 Dulbecco's
elevate Ab1±42/1±40 ratio in vitro and in vivo. Neuron 17, 1005±1013.phosphate-buffered saline (pH 7.1). Immunostaining with mAb 10D5,
6E10, and 4G8 was performed on paraffin-embedded, 10 mm sec- Boteva, K., Vitek, M., Mitsuda, H., de Silva, H., Xu, P.-T., Small, G.,
tions (supported on Vectabond-coated slides). Immunostaining with and Gilbert, J.R. (1996). Mutation analysis of presenilin 1 gene in
the rabbit polyclonal antibodies Ab40 and Ab42 was performed Alzheimer's disease. Lancet 347, 130±131.
on free-floating frozen sections. Prior to immunostaining, paraffin- Cai, X.-D., Golde, T.E., and Younkin, S.G. (1993). Release of excess
embedded sections were deparaffinized by oven heating, followed amyloid b protein from a mutant amyloid b protein precursor. Sci-
by a 3 min incubation in 70% formic acid (longer incubations dimin- ence 259, 514±516.
ish tissue integrity) and further deparaffinization in xylene followed
Campion, D., Brice, A., Dumanchin, C., Puel, M., Baulac, M., De laby washes in 100% ethanol, 95% ethanol, 70% ethanol, and water.
Sayette, V., Hannequin, D., Duyckaerts, C., Michon, A., Martin, C.,Endogenous peroxidase activities were quenched by 30 min incuba-
et al. (1996). A novel presenilin 1 mutation resulting in familial Alzhei-
tions in 3% H2O2 (in methanol) before sections were microwaved mer's disease with an onset age of 29 years. Neuroreport 7, 1582±
for 5±7 min in water, cooled for 5 min, rinsed with water, and then
1584.
washed in Tris-buffered saline (TBS; 0.05 M Tris-Cl [pH 7.6] and
Chapman, J., Asherov, A., Wang, N., Treves, T.A., Korczyn, A.D.,0.25 M NaCl). All free-floating sections stained for Ab were treated
and Goldfarb, L.G. (1995). Familial Alzheimer's disease associatedwith 70% formic acid for 3 min prior to immunostaining. Nonspecific
with S182 codon 286 mutation. Lancet 346, 1040.epitopes were then blocked with 3% normal goat serum and 0.1%
Chartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A.,Triton X-100 in TBS. After 1 hr of blocking, primary antibodies Ab40
Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J.,(Quality Control Biochemicals, Hopkinton, MA), Ab42 (Quality Con-
and Mullan, M. (1991). Early-onset Alzheimer's disease caused bytrol Biochemicals, Hopkinton, MA), 10D5 (a gift from Dr. Dale Shenk,
mutations at codon 717 of the b-amyloid precursor protein gene.Athena Neurosciences, South San Francisco, CA), 6E10 (Kim et al.,
Nature 353, 844±846.1990), or 4G8 (Kim et al., 1990) were diluted to a final concentration
of 5 mg/ml in TBS with 2% normal goat serum and incubated over- Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y.,
night at 48C in a humid chamber. Sections were then washed in TBS Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Selkoe, D.J. (1992).
3 times for 5 min each and incubated with secondary antibodies and Mutation of the b-amyloid precursor protein in familial Alzheimer's
peroxidase-coupled streptavidin as described by the manufacturer disease increases b-protein production. Nature 360, 672±674.
(Vectastain ABC Kit; Vector Laboratories, Incorporated, Burlingame, Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque,
CA). All sections were lightly counter-stained with hematoxylin and G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997).
eosin, following standard histological procedures. Mutant presenilins of Alzheimer's disease increase production of
42-residue amyloid b-protein in both transfected cells and
transgenic mice. Nature Med. 3, 67±72.Acknowledgments
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